Effect of pravastatin on development of left ventricular hypertrophy in spontaneously hypertensive rats

Tsung-Ming Lee1, Mei-Shu Lin2, Tsai-Fwu Chou3, Chang-Her Tsai4, and Nen-Chung Chang5

1Cardiology Section, Department of Medicine, Taipei Medical University and Chi-Mei Medical Center, Tainan; 2National Taiwan University and Department of Pharmacy, National Taiwan University Hospital, Taipei; 3Department of Surgery, Municipal Jen-Ai Hospital, Taipei; 4Cardiology Section, Department of Surgery, National Taiwan University Hospital, Taipei; and 5Cardiology Section, Department of Medicine, Taipei Medical University and Hospital, Taipei, Taiwan

Submitted 4 May 2004; accepted in final form 19 January 2005

Lee, Tsung-Ming, Mei-Shu Lin, Tsai-Fwu Chou, Chang-Her Tsai, and Nen-Chung Chang. Effect of pravastatin on development of left ventricular hypertrophy in spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol 289: H220–H227, 2005. First published January 21, 2005; doi:10.1152/ajpheart.00417.2004.—Endothelin (ET)-1 has been implicated in the development of cardiac hypertrophy. We investigated the effect of pravastatin on development of ventricular hypertrophy in spontaneously hypertensive rats (SHR) and whether the attenuated hypertrophic effect was via reduced ET-1 expression. Normolipidemic SHR were treated with one of the following therapies for 8 wk: vehicle, the nonselective ET receptor antagonists bosentan, pravastatin, mevalonate, hydralazine, or combination of pravastatin + mevalonate from the age of 8 wk at the very early stage of cardiac hypertrophy. Treatment with bosentan and pravastatin significantly decreased left ventricular mass index for body weight and cardiomyocyte sizes isolated by enzymatic dissociation. The myocardial ET-1 levels and preproET-1 mRNA assessed using real-time quantitative RT-PCR were significantly higher (both P < 0.001) in the SHR compared with Wistar-Kyoto rats. The increased tissue ET-1 levels can be inhibited after pravastatin administration. Immunohistochemical analysis confirmed the changes of ET-1. Left ventricular mass index for body weight correlated positively with tissue ET-1 levels (P = 0.0004). A dissociation between the effects of blood pressure and cardiac structure was noted, because pravastatin and hydralazine reduced arterial pressure similarly. Pravastatin-induced effects were reversed by the addition of mevalonate. In conclusion, these results suggest a crucial role of cardiac endothelin system in the early development of ventricular hypertrophy in the SHR. Pravastatin is endowed with cardiac antihypertrophic properties that are independent of its hemodynamic and hypolipidemic effects and appear to be related to their capacity to decrease cardiac ET-1 levels, which is linked to mevalonate metabolism. cardiomycocytes; endothelin-1; immunohistochemistry

Epidemiological studies have demonstrated that increased left ventricular (LV) mass is a risk factor of cardiac morbidity and mortality in patients with hypertension (24). Previous data revealed that LV mass regression reduced cardiovascular complications (11). Hypertrophied myocardium has been shown to generate arrhythmias more readily than normal tissue. Agents that cause the regression of ventricular hypertrophy have been shown to decrease the susceptibility of ventricular arrhythmias (2). Thus the use of LV mass to stratify risk and target antihypertensive therapy has been proposed. To more effectively prevent cardiac hypertrophy and more successfully apply therapeutic interventions, it is important to better understand the factor(s) involved in ventricular growth at the early stage of cardiac hypertrophy, rather than at the established stage, so that therapeutic interventions can be more successfully applied.

Endothelin (ET)-1 gene expression is enhanced in heart in spontaneously hypertensive rats (SHR) (36), an experimental model of genetic hypertension. In SHR, pressure overload initially developed at 8 wk, followed by an active phase of hypertrophic growth between 16 and 20 wk (3). ET-1, a potent growth-promoting peptide derived from endothelial cells, is also produced by cardiac myocytes (30). ET-1 acts as a key autocrine/paracrine mediator to trigger the hypertrophic signaling pathways by activation of extracellular signal-regulated kinase in myocardium via activation of ETAB receptor (43). ET receptor blockade attenuates ventricular hypertrophy (9). Thus treatment with ET antagonists appears to be an attractive alternative to attenuate ventricular hypertrophy.

Pravastatin, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (statin), blocks the mevalonate pathway, reducing cholesterol biosynthesis. Epidemiological studies have demonstrated that the benefit of statin treatment extends to patients with normocholesterolemia (41). Statins exert pleiotropic properties and interfere with signal pathways for hypertrophy, effects that may contribute to their beneficial effects on ventricular hypertrophy (41). Statins have been shown to inhibit ET-1 and to subsequently prevent cellular hypertrophy (41). There are many kinds of statins used clinically that show differences in pharmacological lipophilicity, structure, and solubility. Because lipophilic statins may enter cardiomyocytes, there was a difference in their potency to inhibit mevalonate synthesis in extrahepatic cells (42), which could lead to a different effect on cardiac hypertrophy between lipophilic and hydrophilic statins. Thus, although lipophilic statins have been shown to attenuate ventricular hypertrophy (1, 12), the effects cannot be extrapolated to hydrophilic statins. Whether pravastatin, a hydrophilic statin, has an effect on ventricular hypertrophy remains unknown in SHR. The purpose of this study was to investigate the effect of pravastatin on cardiomyocyte sizes and the role of circulating and cardiac ET systems at the early hypertrophic phase of SHR. To further confirm the role of chronic endothelin activation in the prevention of pravastatin-induced ventricular hypertrophy, we assessed the effect of the nonselective ETAB receptor antagonist bosentan. We also explored the downstream functional significance of reduced ventricular hypertrophy by ventricular pacing.
METHODS

Experimental animals. Male normocholesterolemic SHR had free access to food and water. At 8 wk of age at the very early stage of cardiac hypertrophy, SHR were randomly allocated to one of six groups and treated for 8 wk with vehicle, the nonselective ET receptor antagonist bosentan (10 mg/kg per day), pravastatin (5 mg/kg per day), mevalonate (50 mg/kg per day), hydralazine (10 mg/kg per day), or a combination of pravastatin and mevalonate. The dose of pravastatin used in this study was derived from previous experiments in which pravastatin restored the infarct size-limiting effect of ischemic preconditioning in hyperlipidemic rabbits (39). Because pravastatin has a blood pressure-lowering effect, hydralazine was used to determine the degree to which this decrease in blood pressure is responsible for attenuating cardiac hypertrophy. To further confirm the role of chronic ET activation in the progression of ventricular hypertrophy, we used the nonselective ET 

Real-time RT-PCR. Real-time quantitative RT-PCR was performed from LV samples obtained with the TaqMan system (Prism 7700 sequence detection system; PE Biosystems) as described previously (23). For ET-1, the primers were 5’-TTGCTTGGTGTG-GCTTTCAAA-3’ and 5’-CAAGGATCGTATGACCTAAGG-3’. For glyceraldehyde-3-phosphate-dehydrogenase (GAPDH), the primers were 5’-CTTCAACCACATGGGAGGCC-3’ and 5’-GGC-ATGGACTGTGGTCATGAG-3’. For quantification, ET-1 expression was normalized to the expressed housekeeping gene GAPDH. Reaction conditions were programmed on a computer linked to the detector for 40 cycles of the amplification step.

Plasma and tissue levels of ET-1. Because of a local release of ET-1 and a poor correlation between plasma and tissue ET-1 levels, blood samples from the aorta and LV were obtained for measurements of systemic and local ET-1 levels at the end of the study. For the measurement of cardiac ET-1 levels, the apical two-thirds of the LV was immediately homogenized with a Polytron homogenizer for Triton-X, boiled for 7 min, and centrifuged at 20,000 g for 30 min at 4°C. After measurement of the protein concentration (in pg/mg), the supernatant was stored at −70°C until use. Plasma ET-1 concentration was measured by collecting 4 ml of blood in test tubes containing 2% EDTA (80 μl/ml blood). Blood samples were immediately centrifuged at 3,000 g for 10 min, and the plasmas were stored at −70°C until further analysis was performed. ET-1 was measured using immunoassay (R&D Systems, Minneapolis, MN). Plasma (1 ml) was acidified with 3 ml of 4% acetic acid, and ET-1 was extracted with a Sep-Pak C-18 cartridge. The detection limit was 1 pg/ml for ET-1. Intra-assay and interassay coefficients of variation were 4.5 and 6.6%, respectively.

Cell isolation. Because cardiac hypertrophy is a combination of reactive fibrosis and myocyte hypertrophy, we measured cardiomyocyte sizes from the LV in addition to using myocardial weight to avoid the interference of nonmyocytes. Because immunohistochemical analysis does not permit quantitation of cardiomyocyte sizes, additional groups of rats (n = 5 in each group) were used for measurement of cell sizes. Myocytes were enzymatically isolated according to previously described techniques (23). Briefly, the rats were heparinized, and heart was excised and perfused at a constant flow of 8 ml/min by using a modified Langendorff technique at 37°C with a nominally Ca2+-free, oxygenated Tyrode solution (pH 7.4) containing (in mM) 137 NaCl, 5.4 KCl, 1.1 MgCl2, and 10 HEPES. After 5 min of equilibration, the perfusion was changed to the same solution containing 0.34 mg/ml collagenase (type II; Sigma Chemical, St. Louis, MO). After 8–10 min of digestion, the residual enzyme-containing solution was cleaned by 5 min of perfusion with 0.2 mM Ca2+ Tyrode solution. The heart was then removed from the cannula, and the LV was mechanically dispersed. Random high-power fields of the rodlike relaxed myocytes with clear striations were selected in phase-contrast illumination mode of confocal microscopy (LSM-410 Invert; Zeiss) to eliminate selection bias. At least 100 cells from each selection were selected for measurement of cell area, length, and width, and mean values were used as an individual value for each section.

Statistical analysis. Results are presented as means ± SD. Differences among the groups of rats were tested using two-way ANOVA. Subsequent analysis for significant differences between the two groups was performed with a multiple comparison test (Scheffé’s method). Electrophysiological data (scoring of programmed electrical stimulation-induced arrhythmias) were compared using a Kruskal-Wallis test followed by a Mann-Whitney test. An interaction term of pravastatin and mevalonate effects was incorporated into the model. Correlation between the degree of attenuated cardiomyocyte hyper-

Downloaded from http://ajpheart.physiology.org/ by 10.220.33.6 on June 14, 2017

AJP-Heart Circ Physiol • VOL 289 • JULY 2005 • www.ajpheart.org
trophy and the tissue ET-1 levels was assessed using Pearson’s correlation coefficient. The significant level was assumed at a value of \( P < 0.05 \).

RESULTS

Pravastatin does not lower serum cholesterol in rats, consistent with the notion that compensatory increases in hepatic enzyme production were observed in rats treated with statins. These data indicate the nonlipid effect of pravastatin on ventricular hypertrophy.

Hemodynamic data. During the 8-wk treatment period, pravastatin decreased systolic blood pressure by 39 mmHg without, however, normalizing it (Table 1). Chronic antihypertensive treatment for 8 wk with hydralazine led to a similarly lower systolic blood pressure compared with pravastatin-treated SHR. Heart rate did not differ among all groups. The maximal rate of LV pressure rise (\( +dP/dt \)) was significantly increased in SHR compared with WKY rats. Compared with untreated SHR, bosentan and pravastatin decreased heart weight-to-body weight compared with WKY rats. Compared with untreated SHR, bosentan and pravastatin decreased heart weight-to-body weight ratios by 7 and 8%, respectively (Table 1). Chronic antihypertensive treatment for 8 wk with hydralazine led to a similarly lower systolic blood pressure compared with pravastatin-treated SHR. Heart rate did not differ among all groups. The maximal rate of LV pressure rise (\( +dP/dt \)) was significantly increased in SHR compared with WKY rats.

Morphometric studies. Chronic drug treatment did not modify the increase of body weight with age. Table 1 shows LV weight-to-body weight ratios of animals from each group. Before treatment, the SHR groups had equivalent baseline body weights. At the end of the treatment period, body weights were similar in the SHR groups. Untreated SHR showed LV hypertrophy, with a significant increase of 40% in the ratio of LV weight to body weight compared with pravastatin-treated SHR. Heart rate did not differ among all groups. The maximal rate of LV pressure rise (\( +dP/dt \)) was significantly increased in SHR compared with WKY rats.

Table 1. Cardiac morphology, hemodynamics, cholesterol, and plasma and tissue ET-1 concentrations among groups

<table>
<thead>
<tr>
<th>Parameters</th>
<th>SHR</th>
<th>WKY</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of rats</td>
<td>10</td>
<td>10</td>
</tr>
<tr>
<td>BW, g</td>
<td>325±16</td>
<td>313±16</td>
</tr>
<tr>
<td>LVW/BW, mg/g</td>
<td>3.03±0.25</td>
<td>2.97±0.10</td>
</tr>
<tr>
<td>HR, beats/min</td>
<td>406±22</td>
<td>405±20</td>
</tr>
<tr>
<td>LVESPV, mmHg</td>
<td>218±13</td>
<td>199±15</td>
</tr>
<tr>
<td>LVEDPV, mmHg</td>
<td>6±2</td>
<td>5±2</td>
</tr>
<tr>
<td>+dP/dt, mmHg/s</td>
<td>9.108±798</td>
<td>8.980±1224</td>
</tr>
<tr>
<td>Plasma cholesterol, mg/dl</td>
<td>45±29</td>
<td>48±12</td>
</tr>
<tr>
<td>Plasma ET-1, pg/ml</td>
<td>1.42±0.41</td>
<td>1.42±0.10</td>
</tr>
<tr>
<td>LV ET-1, pg/mg tissue</td>
<td>2.69±0.70</td>
<td>2.87±0.80</td>
</tr>
</tbody>
</table>

Values are means ± SD. BW, body weight; ET-1, endothelin-1; HR, heart rate; LVEDPV, left ventricular end-diastolic pressure; LVESPV, left ventricular end-systolic pressure; LVW, left ventricular weight; Meval, mevalonate; Prava, pravastatin; WKY, Wistar-Kyoto rats. * \( P < 0.05 \) compared with spontaneously hypertensive rat (SHR) groups. † \( P < 0.05 \) compared with vehicle-, mevalonate-, combination-, and hydralazine-treated groups. \( \delta P < 0.05 \) compared with vehicle-, bosentan-, mevalonate-, and combination-treated groups.
study showing that the density of ETB receptor is increased hypertrophy. Our results were consistent with those of a recent proET-1 mRNA and ET-1 protein levels, developed ventricular acting through the corresponding increase of ventricular pre-
observed at the cellular level as well as the organ levels. SHR, studies (5). Hypertrophic changes in the heart of SHR were
pressure pattern of hypertrophy that is consistent with previous
significantly greater in SHR cardiomyocytes, indicative of the
significantly greater than those in WKY rats. Cell width was
dimensional cell surface area of myocytes in SHR were sig-
cardiac remodeling in SHR. In this study, width and two-
dimensional cell surface area of myocytes in SHR were sig-
ificance greater than those in WKY rats. †
Fig. 1. Inducibility quotient of ventricular arrhythmias by programmed elec-
trical stimulation. *P < 0.05 compared with Wistar-Kyoto (WKY) rats, bosentan-treated spontaneously hypertensive rats (SHR), and pravastatin-
treated SHR. Meval, mevalonate; Prava, pravastatin.

DISCUSSIONS

The present study demonstrates for the first time that prav-
astatin prevents ongoing cardiac hypertrophy at the early hy-
pertrophic phase of SHR, independently of hemodynamic and
lipid changes. The present study demonstrates three novel
findings through combined use of molecular, biochemical, and
morphological methods. First, ET-1 levels are responsible for
cardiac remodeling in SHR. In this study, width and twodimensional cell surface area of myocytes in SHR were sign-
ificantly greater than those in WKY rats. Cell width was signifi-
cantly greater in SHR cardiomyocytes, indicative of the
pressure pattern of hypertrophy that is consistent with previous
studies (5). Hypertrophic changes in the heart of SHR were
observed at the cellular level as well as the organ levels. SHR, acting through the corresponding increase of ventricular preproET-1 mRNA and ET-1 protein levels, developed ventricular hypertrophy. Our results were consistent with those of a recent study showing that the density of ETB receptor is increased during active hypertrophy at the age of 16–24 wk in SHR (21). This notion was further confirmed by directly administering an ET receptor blocker. Second, the beneficial effects of pravasta-
atin on the prevention of ventricular hypertrophy may be
associated with reduced expression of preproET-1 mRNA and
ET-1 protein levels independently of hemodynamic changes.
Hydralazine did not reduce any of the parameters despite
similar inhibition of blood pressure. Third, the inhibitory effect
of pravastatin is specifically prevented by the addition of
exogenous mevalonic acid, indicating that the inhibitory ef-
cets of the drug are caused by blockade of the pathways
leading to isoprenoid synthesis. These combined results indi-
cate that pravastatin prevents progression of ventricular hyper-
trophy through attenuation of mevalonate-dependent tissue
ET-1 levels in SHR.

Mechanisms. The present study suggests that pravastatin affects myocyte function (attenuated pacing-induced arrhyth-
rias) and growth (attenuating myocardial hypertrophy). The
mechanisms by which pravastatin attenuates cardiac hypertro-
phy remain to be defined. Clearly, hemodynamics did not play
a major role in the process. Various statins have been shown to
reduce blood pressure in patients (10) and animals (37). Glorioso et al. (10) have shown hemodynamic improvement after
16-wk therapy with pravastatin in hypertensive patients. How-
ever, the mechanism by which pravastatin prevents cardiac
hypertrophy is probably not due to its antihypertensive effect
alone. In this study, we found that chronic treatment of SHR
with hydralazine did not prevent ongoing cardiac hypertrophy
even though it was as effective as pravastatin in lowering blood
pressure in SHR. Thus, although we demonstrated hyperkinetic
circulation in relatively young SHR, hemodynamics did not play
a major role in attenuation of cardiac hypertrophy in
pravastatin-treated SHR. Further evidence of this is our finding
that LV weight correlates with tissue ET-1 levels but not with
blood pressure. Thus some factors other than high blood
pressure may contribute to the pathogenesis of cardiac hyper-
trophy in SHR. These findings support the notion that prava-
statin has direct tissular effects dissociated from its hemody-
namic systemic effects.

Fig. 2. Left ventricular (LV) preproendothelin-1 (preproET-1) mRNA levels in WKY rats and vehicle-treated, pravastatin-treated, mevalonate-treated, prav-
astatin + mevalonate (combination)-treated, and hydralazine-treated SHR.
Each mRNA level was corrected for an mRNA level of glyceraldehyde-3-
phosphate dehydrogenase (GAPDH). Values are means ± SD. *P < 0.05 compared with WKY rats. †P < 0.05 compared with vehicle-, mevalonate-, combination-, and hydralazine-treated SHR.

Table 2. Characteristics of isolated cardiomyocytes

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Vehicle</th>
<th>Bosentan</th>
<th>Pravastatin</th>
<th>Mevalonate</th>
<th>Pravastatin + Mevalonate</th>
<th>Hydralazine</th>
<th>WKY</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of animals</td>
<td>5</td>
<td>5</td>
<td>5</td>
<td>5</td>
<td>5</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>Myocyte length, μm</td>
<td>139±27</td>
<td>138±20</td>
<td>135±20</td>
<td>138±25</td>
<td>137±21</td>
<td>138±16</td>
<td>134±15</td>
</tr>
<tr>
<td>Myocyte width, μm</td>
<td>24±3</td>
<td>22±2*</td>
<td>21±2*</td>
<td>26±4</td>
<td>26±3</td>
<td>25±2</td>
<td>21±3*</td>
</tr>
<tr>
<td>Measured myocyte areas, μm²</td>
<td>3,803±213</td>
<td>3,098±146*</td>
<td>3,170±157*</td>
<td>3,647±229</td>
<td>3,561±207</td>
<td>3,872±102</td>
<td>3,010±192*</td>
</tr>
</tbody>
</table>

Values are means ± SD. *P < 0.05 compared with vehicle-, mevalonate-, combination-, and hydralazine-treated groups.
Our observations showed that reduced pravastatin-related ET-1 levels might play crucial roles in attenuation of myocyte hypertrophy. The role of ET-1 in pathogenesis of myocyte hypertrophy was further confirmed by directly blocking ET receptors. Attenuated cardiac hypertrophy accompanied by reduced cardiac ET-1 indicated that autocrine/paracrine ET-1 secretion pathways could be a factor in the proliferative process blunted by pravastatin. The addition of mevalonate to pravastatin-treated rats impaired not only their ability to attenuate cellular hypertrophy but also their ability to suppress ET-1 levels. Thus blocking the mevalonate pathway is a critical step in the mechanism of pravastatin-induced attenuation of ET-1 levels. The molecular mechanism of noncholesterol effects of statins is the inhibition of the isoprenoid intermediates of the cholesterol pathway. Isoprenoids are essential for the function of signal transduction molecules of the Rho family (20). Regulation of Rho activity by statins is separate from that of statins on lipids. Inhibition of Rho signaling by statins can activate peroxisome proliferator-activated receptors (6), which in turn suppress ET-1 secretion (34). In addition, decreases in regional ET-1 concentrations may result from decreases in ET-1 production and/or increased ET-1 clearance. The production of ET-1 begins with the cleavage of the translational product preproET-1. Our results show inhibition of pravastatin on preproET-1 mRNA at the transcription levels. Thus decreases in ET-1 production may play a major role in regional ET-1 changes. Together, both secretion and synthesis of ET-1 may be inhibited after the administration of pravastatin reduces tissue ET-1 levels, which attenuated progression of cardiomyocyte hypertrophy.

There are controversies as to the role of ET-1 in the pathogenesis and maintenance of ventricular hypertrophy in SHR. Some reports have shown that the ET system does not appear to play an important role in ventricular hypertrophy in SHR (25). However, others have suggested a causal role for ET in the development of hypertension in SHR (29). These discrepancies may be due to differences in ages of hypertensive rats that were associated with different pathological and physiological conditions during exposure to different developmental periods. It has been suggested that different stages of hypertension may be differentially regulated in SHR (3). Ito et al. (14) have proposed that cardiac ET-1 may act as an initiating hypertrophic factor during the early stage of pressure overload but that other factors, such as the renin-angiotensin system, may take over as maintaining factors during the late stage of pressure overload. Our studies were performed in quite young animals, i.e., 16-wk old at the end of treatment, in which the development of hypertrophy is at its early stages. Our data are consistent with the notion that early ET-1 production acts as a triggering factor to hypertrophy. Indeed, our results are com-

![Fig. 3. Immunohistochemical microscopy of ET-1 (magnification ×200). Positive staining for ET-1 (brown) was distributed in the myocardium. The intensity of ET-1 was significantly lower in pravastatin-treated SHR (C) than in SHR treated with vehicle (B), mevalonate (D), pravastatin + mevalonate (E), and hydralazine (F). A: WKY rats. Bar, 100 μm.](http://www.ajpheart.org)
Angiotensin system and the ET-1 system (15). Angiotensin II
In vitro studies have demonstrated cross talk between the
potential role of angiotensin II, which may interact with statins.
Concerning the mechanisms involved in the attenuation of
hypertrophy by attenuating the enzyme activities (40). Finally,
cardiac hypertrophy development. Statins may prevent cardiac
stage in 7-wk-old SHR compared with WKY rats. Mitochon-
drondial NADP-isocitrate dehydrogenase adducts in
oxide synthase knockout mice. Third, Benderdour et al. (4)
et al. (26) have shown increased LV mass in endothelial nitric
may also result from attenuation of nitric oxide inhibition. Liu
(22). Second, blunting by pravastatin of antihypertropic effect
radicals alleviated the development of cardiac hypertrophy,
pravastatin-induced attenuated LV mass cannot be attributed solely to cardiac tissue ET-1 levels, which stresses the importance of other factors. First, blockade of free radicals alleviated the development of cardiac hypertrophy, and pravastatin was shown to inhibit production of free radicals (22). Second, blunting by pravastatin of antihypertropic effect may also result from attenuation of nitric oxide inhibition. Liu et al. (26) have shown increased LV mass in endothelial nitric oxide synthase knockout mice. Third, Benderdour et al. (4) have shown that NADP-isocitrate dehydrogenase adducts in the heart have significantly increased at the prehypertensive stage in 7-wk-old SHR compared with WKY rats. Mitochon-
drondial NADP-isocitrate dehydrogenase activity is crucial for cardiac hypertrophy development. Statins may prevent cardiac hypertrophy by attenuating the enzyme activities (40). Finally, concerning the mechanisms involved in the attenuation of pravastatin-induced ET-1, it also is attractive to consider a potential role of angiotensin II, which may interact with statins. In vitro studies have demonstrated cross talk between the angiotensin system and the ET-1 system (15). Angiotensin II
has been shown to induce ET-1 synthesis in cardiomyocytes in vitro (31). Lovastatin has been shown to inhibit activity of angiotensin II (31), thus accounting for the downregulation effect on ET-1 protein expression (7). Although pravastatin has little effect on cardiac angiotensin activity (19), we cannot rule out the possibility of decreased cardiac angiotensin activity secondarily to an inhibition of ET-1 exerted by the agent. Complex interactions among angiotensin II, free radical, nitric oxide, and NADP-isocitrate dehydrogenase activity could affect cardiac hypertrophy. Therefore, a variety of upstream regulators could interfere with hypertrophic signaling path-
ways. The failure to completely abrogate the hypertrophic process was not surprising in view of the underlying complex hypertrophic process, which is unlikely to be amenable to one therapeutic intervention. Extensive investigation of such pathways and the mechanisms by which pravastatin attenuates cardiac hypertrophy require additional studies.

Arhythmias. LV hypertrophy is associated with structural, hemodynamic, and electrophysiological abnormalities. Our results showed that attenuated ventricular hypertrophy after pravastatin administration has benefits in the incidence of ventricular arrhythmias. Myocyte hypertrophy may cause a lengthening of action potential duration, which may generate arrhythmias, via downregulation of the transient outward current (I\textsubscript{to}) as well as the delayed and background rectifier current (I\textsubscript{k1}, I\textsubscript{k4}) (18). Rials et al. (33) have shown that regression of cardiac hypertrophy leads to normalization of the prolonged action potential. Furthermore, ET-1 has been shown to directly inhibit potassium channel and act as an important mediator of arrhythmogenesis (17), which was consistent with the antiarrhythmic effect of pravastatin by attenuation of ET-1 levels. In fact, our results were consistent with those of Matsumoto et al. (28), showing that long-term treatment with ET-1 blockers inhibits electrical remodeling and suppresses ventricular arrhythmias. Third, SHR have been shown to have increased sympathetic tone (38), a key trigger of fatal arrhythmias. Statins may decrease ventricular vulnerability by normalizing sympathetic control (32). Together, regardless of the relative importance of each of these factors, all of the changes caused by pravastatin are compatible with our understanding of benefi-
cial effects on induction of ventricular arrhythmias.

Study limitations. A potential problem with the present study is whether cardiomyocytes contribute to increased ET-1 expression. Although immunohistochemical analysis of the LV revealed the presence of ET-1 immunoreactivity in this study, a number of other cell types not normally present in the myocardial tissue to any substantial degree may also produce ET-1 and may contribute to the increased expression during ventricular hypertrophy. These include vascular endothelial cells, smooth muscle cells, and fibroblasts (30). Because we did not perform a double staining for ET-1 and a specific myocyte lineage, we cannot rule out the possibility that non-
myocytes may provide an alternative source of ET-1 to initiate ventricular hypertrophy.

In conclusion, the results of the present study show that SHR at the early stage of hypertension have an increase of pre-
proET-1 mRNA and the mature ET-1 peptide. The finding can be rationalized mechanistically, suggesting a pathogenetic role of regional ET-1 expression in the development of myocardial hypertrophy. Early intervention with pravastatin can reduce the inducibility of ventricular arrhythmias as a result of attenuated
ventricular hypertrophy, probably through the ET-1 pathway, which is linked to malateval metabolism. The pharmacological profile of pravastatin gives new perspectives in the early treatment of ventricular hypertrophy.

ACKNOWLEDGMENTS

We thank In-Ping Cheng, Li-Lan Chien, Shu-Ping Sun, and Fang-Chin Lee for excellent technical assistance and Yu-Wei Chao for performing real-time RT-PCR analysis.

GRANTS

This work was supported by Chi-Mei Medical Center Grants CMHFT 9201, CMHFR9303, CMHFR9307, and CM-TMU9305. Bosentan was a generous gift from Actelion Pharmaceuticals Ltd., Allschwil, Switzerland. Pravastatin was a generous gift from Sankyo Pharmaceuticals Ltd., Tokyo, Japan.

REFERENCES


